Aquila has designed in vitro assays to best mimic in vivo immune activation, allowing assessment of your compound’s effects on the activation and differentiation of innate and adaptive immune cells (monocytes, macrophages, DCs, T cells, B cells), using standard and more sophisticated immunoassays. These can be configured to different pathological settings (e.g. Th2/allergy, Th1 or Th17/autoimmune disease).

In addition to the standard immune cell assays available, Aquila has developed a phased screening platform to specifically assess myelin-reactive T cell responses in vitro before progression to the in vivo MBP-Tracker EAE model. The MBP-Tracker EAE model is unique in that traceable, antigen-reactive pathogenic CD4+ T cells can be isolated and studied ex vivo, enabling mode of action, and efficacy data to be analysed.

Aquila has extensive immunology experience, research expertise and many strong academic links. Please contact us if you have a specific project of interest.


In Vitro Immunology
Aquila has a suite of in vitro  and in vivo assays specifically relevant to investigation of test compounds with potential immunomodulatory effects. Information gained from these assays will give you greater confidence at the key decision point of lead compound selection before in-clinic testing. In vitro and in vivo assays include:


In Vivo Immunology


We’d be happy to discuss any service or product you may be interested in.

Aquila BioMedical Ltd.
Nine, Edinburgh BioQuarter
9, Little France Road
EH16 4UX

Tel: +44 (0) 131 658 5164